This is the logo of the provider
AASLD 2025 7 - 10 November 2025

SomaSignal defined MASH disease components are prognostic of secondary cardiovascular disease – A post-hoc analysis of the SELECT trial

Authors :

Arun J. Sanyal1; Steen Ladelund2; Michelle T. Long2; Sune Boris Nygård2; Adel Belloum2; Jörn M. Schattenberg3

Affiliations
View Details Hide Details
This is the logo of the provider
{{ getPageNum(PDFPage) }}
Download poster (.pdf)
Keywords
MASH
Congress poster
GLP-1 RA
Semaglutide
PHASE 3 (RCT)